Dynavax price target raised to $15 from $14 at H.C. Wainwright H.C. Wainwright analyst Edward White raised the firm's price target on Dynavax Technologies to $15 from $14 and reiterates a Buy rating on the shares. Dynavax and Clover Biopharmaceuticals this morning announced plans to initiate a global Phase 2/3 efficacy trial with Clover's S-trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum. CpG 1018 is the adjuvant used in Heplisav-B, Dynavax's marketed vaccine, White tells investors in a research note. The analyst reminds investors that Dynavax currently has five collaborations in place that are focused on developing COVID-19 vaccines. He estimates CpG 1018 adjuvant sales for COVID-19 vaccines of $100M in 2021
Read more at:
https://thefly.com/n.php?id=3238123

